Publication details
Využití risankizumabu v léčbě špatně spolupracujícího pacienta s těžkou formou psoriázy
| Title in English | The use of risankizumab in treatment of non compliant patient with severe psoriasis |
|---|---|
| Authors | |
| Year of publication | 2020 |
| Type | Chapter of a book |
| Citation | |
| Description | Risankizumab is a humanized immunoglobulin G1 monoclonal antibody that binds with high affinity to the p19 subunit and selectively inhibits interleukin 23 (IL-23). It is registered for treatment of moderate to severe plaque psoriasis in adult patients. Risankizumab administered every 12 weeks demonstrated consistently high and durable efficacy and favourable safety profile. The case report describes progress and treatment of severe psoriasis in non compliant male patient. |